Developing new technologies to create inhibitors for carbohydrate-binding proteins
Official title: Technologies for Directed Evolution of Glycoaptamers
Funded at Brandeis University · NIH-10907010 · Data updated 2026-11-12
This study is working on new tools to help find ways to block certain proteins that are important in diseases like cancer and autoimmune disorders, aiming to create special molecules that can target these proteins and improve treatment options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brandeis University NIH-funded |
| Lab location | 1 site (Waltham, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $317,178 |
| NIH project number | 5R01GM151492-02 |
| Project ID | NIH-10907010 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals suffering from conditions related to carbohydrate-binding protein interactions, such as atherosclerosis, diabetes, or certain cancers.
✕Less likely to help
Patients with conditions unrelated to carbohydrate-binding proteins or those who do not have a significant immune or metabolic component may not benefit from this research.
What this research studies
This research focuses on creating innovative technologies to quickly discover inhibitors that target carbohydrate-binding proteins (CBPs). These proteins play a crucial role in various biological processes, including how cells communicate and how diseases like cancer and autoimmune disorders develop. The project aims to develop two types of glyco-F-RNA aptamers that can selectively bind to specific CBPs, enhancing their effectiveness in disrupting harmful interactions in the body. By using advanced techniques, the researchers hope to provide new tools for treating conditions linked to CBPs.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for a range of diseases, including cancer, autoimmune disorders, and cardiovascular diseases.
How similar studies have gone: While the approach of developing glyco-F-RNA aptamers is innovative, similar strategies targeting carbohydrate interactions have shown promise in other research, indicating potential for success.
Where this research is happening
-
Brandeis University
Waltham, United States Active
Researchers
- Principal investigator: Krauss, Isaac Jonathan — Brandeis University
- Study coordinator: Krauss, Isaac Jonathan
Related research
Other NIH-funded projects on the same topics.
-
Unwinding SNAP aid and its effect on healthcare and disparities
A large study will look at how cutting back food assistance like SNAP changes healthcare use and outcomes, especially for people with differing levels of food insecurity.
-
Roles of Recycling Endosomes in Neuronal EV Cargo Traffic
A scientist at Brandeis University is studying how brain cells control the tiny vesicles they release, which may affect memory loss in Alzheimer’s disease.
-
Sulfur-stabilized HIV glycoconjugates to help create powerful bnAbs
Researchers are testing sugar-coated HIV vaccine components in animals to see if they can better trigger broadly-protective antibodies.
-
Cycling Molecular Assemblies to Target Golgi Traffic in Cancer Cells
A novel, first-of-its-kind approach uses tiny, self-organizing molecular structures to selectively disrupt Golgi trafficking in cancer cells, aiming to influence how cancer cells grow and respond to signals.
-
How low oxygen and genetic tweaks may repair mitochondrial problems linked to Alzheimer’s and other disorders
A Johns Hopkins-style? (Note: institution specified later) patient-facing overview: researchers will study tiny cell power stations in mitochondria to see if low-oxygen conditions and specific genetic changes can fix problems associated with Alzheimer's disease and related dementias.
-
Synthesis of thioaminoketal antimicrobial peptides and how they work
Researchers are developing new antimicrobial peptides called sactipeptides and figuring out precisely how they kill bacteria.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.